2. Search Result
Search Result
Results for "

LC3

" in MedChemExpress (MCE) Product Catalog:

65

Inhibitors & Agonists

2

Biochemical Assay Reagents

4

Peptides

14

Natural
Products

2

Recombinant Proteins

1

Isotope-Labeled Compounds

4

Antibodies

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-130258
    LC3-mHTT-IN-AN1

    		Atg8/LC3 ATTECs Autophagy Neurological Disease
    LC3-mHTT-IN-AN1 (Compound AN1) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins. LC3-mHTT-IN-AN1 reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons .
    LC3-mHTT-IN-AN1
  • HY-130259
    LC3-mHTT-IN-AN2

    		Atg8/LC3 ATTECs Autophagy Neurological Disease
    LC3-mHTT-IN-AN2 (Compound AN2) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins. LC3-mHTT-IN-AN2 reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons .
    LC3-mHTT-IN-AN2
  • HY-W688687
    XIE62-1004-A

    		Autophagy p62 Atg8/LC3 Others
    XIE62-1004-A is an inducer of p62-LC3 interaction. XIE62-1004-A can bind to the ZZ-domain of p62, inducing p62 oligomerization and activating p62-dependent autophagy .
    XIE62-1004-A
  • HY-161872
    LC3in-C42

    		Autophagy p62 Cancer
    LC3in-C42 is a cell-active LC3A/B and autophagy covalent inhibitor. LC3in-C42 selectively inhibits the binding of P62 to LC3A/B in vitro and at the cellular level like D5 and can function on a lower concentration .
    LC3in-C42
  • HY-168891
    LC3B recruiter 1

    		Atg8/LC3 Others
    LC3B recruiter 1 (compound 33R) is an LC3B recruiter fragment. LC3B recruiter 1 directly interacts with LC3B with a KD value of 2.87 µM .
    LC3B recruiter 1
  • HY-168892
    LC3B recruiter 2

    		ATTECs Atg8/LC3 Autophagy Cancer
    LC3B recruiter 2 (34R) is an LC3B recruiter and a component of the autophagy-lysosome pathway degradation system (ATTEC, Autophagy-Tethering Compounds), which directly binds to LC3B. LC3B recruiter 2 binds to CDK9 inhibitor SNS-032 (HY-10008) through a linker, forming an ATTEC that targets the degradation of the CDK9 and Cyclin T1 complex (with inhibitory effects on both). Therefore, LC3B recruiter 2 exerts activity through the LC3B-dependent autophagy-lysosome pathway, interfering with the cell cycle of cancer cells, thus exhibiting antitumor activity .
    LC3B recruiter 2
  • HY-176045
    LC3B ligand 2

    		Ligands for E3 Ligase Cardiovascular Disease Cancer
    LC3B ligand 2 is a ligand for E3 ubiquitin ligase. LC3B ligand 2 can be connected to the ligand for protein by a linker to form PROTAC PCSK9 autophagic degrader 2 (HY-176043). PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .
    LC3B ligand 2
  • HY-168897
    LC3B ligand 1

    		Ligands for Target Protein for PROTAC Others
    LC3B ligand 1 is a ligand for the target protein of PROTAC and can be used for the synthesis of PROTAC CDK9 autophagic degrader 1 (HY-168896) .
    LC3B ligand 1
  • HY-168347
    TH152

    		Atg8/LC3 Others
    TH152 is a reversible, pan ligand for LC3/GABARAP with a KD of 2 µM. LC3/GABARAP is an autophagy associated protein .
    TH152
  • HY-121546
    ALLO-1

    		Atg8/LC3 Autophagy Cancer
    ALLO-1, an autophagy receptor, is essential for autophagosome formation around paternal organelles and directly binds to the worm LC3 homologue LGG-1 through its LC3-interacting region (LIR) motif .
    ALLO-1
  • HY-162588
    MC-ND-18

    		ATTECs NOD-like Receptor (NLR) Inflammation/Immunology
    MC-ND-18 is an ATTEC degrader of NLRP3 through autophagic mechanisms, with the DC50 of 125.5 nM in THP-1 cell. MC-ND-18 is composed of a NLRP3 ligand, linker and LC3 ligand .
    MC-ND-18
  • HY-P10416
    Q14

    Q14 peptide

    		 Deubiquitinase Mitophagy Others Neurological Disease
    Q14 is a polypeptide derived from the USP30 (ubiquitin specific peptidase 30) transmembrane (TM) domain with the ability to inhibit the deubiquitination activity of USP30 (IC50=57.2 nM). Q14 reduces USP30 activity by inhibiting the interaction between the USP30 transmembrane domain and its catalytic domain. Q14 peptide contains the LC3 interaction region (LIR) motif, which enables it to bind to the LC3 and accelerate the formation of autophagosomes, thereby promoting mitophagy. Q14 can be used in the study of neurodegenerative diseases as well as mitochondrial quality control and cell metabolism .
    Q14
  • HY-168206
    Autophagy-IN-6

    		Autophagy Cancer
    Autophagy-IN-6 (compound 1u) is a lysosomotropic autophagy inhibitor and can induces LC3-II protein accumulation. Autophagy-IN-6 shows anti-proliferative activity .
    Autophagy-IN-6
  • HY-146307
    TrxR-IN-3

    		TrxR Cancer
    TrxR-IN-3 (Compound 2c) is a potent inhibitor of TrxR. TrxR-IN-3 exhibits potent antiproliferative activities against five human cancer cell lines, especially against breast tumor cells. TrxR-IN-3 increases ROS levels and resulted in marked apoptosis by regulating apoptosis-related proteins expressed in the breast cancer cells. TrxR-IN-3 also triggers the formation of autophagosomes and autolysosomes by promoting the expression of LC3-II and Beclin-1 and diminishing the expression of LC3-I and p62 proteins .
    TrxR-IN-3
  • HY-125535
    OSU-53

    		AMPK mTOR Autophagy Atg8/LC3 Cancer
    OSU-53 is an orally active AMPK activator (EC50: 0.3 μM) and a direct mTOR inhibitor. OSU-53 induces autophagy and increases conversion of LC3 I to LC3 II. OSU-53 also modulates energy homeostasis by suppressing fatty acid biosynthesis and shifting the metabolism to oxidation by up-regulating the expression of PGC1α and NRF-1. OSU-53 has antitumor activity in various tumor models, such as breast cancer and thyroid cancer .
    OSU-53
  • HY-P4532
    Ac-Leu-Val-Lys-Aldehyde

    		Cathepsin Neurological Disease
    Ac-Leu-Val-Lys-Aldehyde is a potent cathepsin B inhibitor with IC50s of 4 nM. Ac-Leu-Val-Lys-Aldehyde significantly reduces quinolinic acid (HY-100807)-induced striatal cell death and causes accumulation of LC3-II .
    Ac-Leu-Val-Lys-Aldehyde
  • HY-10542A
    (Z)-GW 5074

    		Atg8/LC3 Raf Neurological Disease
    (Z)-GW 5074 is a compound which interacts with both mHTT (mutant huntingtin protein) and LC3, but not but not with the wild-type HTT protein. (Z)-GW 5074 inhibits c-Raf, shows no effect on autophagy, and is effective for neurodegenerative disorder .
    (Z)-GW 5074
  • HY-N4180
    Pennogenin 3-O-beta-chacotrioside

    		Atg8/LC3 Autophagy Cancer
    Pennogenin 3-O-beta-chacotrioside is an active component isolated from Paris polyphylla, modulates autophagy via increasing the expressions of autophagy-related proteins LC3 and Beclin-1. Anti-colorectal cancer activity .
    Pennogenin 3-O-beta-chacotrioside
  • HY-N8441
    Neriifolin

    17β-Neriifolin

    		 Atg8/LC3 Na+/K+ ATPase Apoptosis Beclin1 Cardiovascular Disease Inflammation/Immunology Cancer
    Neriifolin, a CNS-penetrating cardiac glycoside, is an inhibitor of the Na +, K +-ATPase. Neriifolin can target beclin 1, inhibits the formation of LC3-associated phagosomes and ameliorates experimental autoimmune encephalomyelitis (EAE) development. Neriifolin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells [2.
    Neriifolin
  • HY-111287
    Autophagonizer

    DK-1-49

    		 Autophagy Cancer
    Autophagonizer (DK-1-49) is a small molecule autophagy inducer that results in an accumulation of autophagy-associated LC3-II and enhances levels of autophagosomes and acidic vacuoles. Autophagonizer inhibits cell viability and induces cell death in not only cancer cells but also Bax/Bak double-knockout cells with EC50 values of 3-4 μM .
    Autophagonizer
  • HY-P3148
    Astin B

    		p62 Atg8/LC3 Apoptosis Autophagy Reactive Oxygen Species JNK Bcl-2 Family Caspase Metabolic Disease
    Astin B is a orally active and potent cyclic pentapeptide, that can be isolated from Aster tataricus. Astin B has hepatotoxic effects in vitro and in vivo and that hepatic injury was primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B induces autophagy in L-02 cells, increases LC3-II and decreases p62 expression .
    Astin B
  • HY-16121
    CAA-0225

    		Cathepsin Others
    CAA-0225 is a tissue protease L inhibitor that inhibits rat liver tissue protease L with a IC50 value of 1.9 nM. CAA-0225 can participate in the degradation of autophagosome membrane markers LC3-II and GABARAP (HY-P72639), improve cardiac function in mice with reperfusion injury, and kill and eliminate Trypanosoma brucei parasites [1][2][3].
    CAA-0225
  • HY-W250118
    Phosphatidylethanolamine

    		Liposome Autophagy Neurological Disease Metabolic Disease
    Phosphatidylethanolamine is an orally active phospholipid widely present in organisms. Phosphatidylethanolamine participates in the formation of autophagosome membrane as a lipid anchor of autophagy-related protein Atg8/LC3. Phosphatidylethanolamine enhances Autophagic flux, promotes cell differentiation, regulates lipid droplet fusion, delays aging, and also affects lipid metabolism and membrane integrity [3] .
    Phosphatidylethanolamine
  • HY-N1399
    Androsin

    		AMPK PI3K Autophagy Metabolic Disease Inflammation/Immunology
    Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth. Androsin activates AMPKα/PI3K/Beclin1/LC3 signaling pathway, inhibits SREBP1c/FASN signaling pathway. Androsin can be used in research of asthma and non-alcoholic fatty liver disease (NAFLD). Androsin is orally active .
    Androsin
  • HY-146052
    Autophagy inducer 3

    		Atg8/LC3 Autophagy Cancer
    Autophagy inducer 3 has autophagy induced activity. Autophagy inducer 3 possesses robust autophagic cell death in diverse cancer cells sparing normal counterpart. Autophagy inducer 3 induces lethal autophagy by formation of characteristic autophagic vacuoles, LC3 puncta formation, upregulation of signature autophagy markers like Beclin and Atg family proteins .
    Autophagy inducer 3
  • HY-N1399R
    Androsin (Standard)

    		AMPK PI3K Autophagy Metabolic Disease Inflammation/Immunology
    Androsin (Standard) is the analytical standard of Androsin. This product is intended for research and analytical applications. Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth. Androsin activates AMPKα/PI3K/Beclin1/LC3 signaling pathway, inhibits SREBP1c/FASN signaling pathway. Androsin can be used in research of asthma and non-alcoholic fatty liver disease (NAFLD). Androsin is orally active .
    Androsin (Standard)
  • HY-155226
    FLT3-IN-21

    		FLT3 Apoptosis Cancer
    FLT3-IN-21 (compound LC-3) is a potent FLT3 inhibitor (IC50: 8.4 nM) and induces apoptosis. FLT3-IN-21 can arrest the cell cycle in the G1 phase and inhibit the proliferation of FLT3-ITD-positive AML cells MV-4-11 (IC50: 5.3 nM). In mice, FLT3-IN-21 (10 mg/kg/d) inhibited tumor growth in the MV-4-11 xenograft model (TGI=92.16%) .
    FLT3-IN-21
  • HY-168640
    RIP3 activator 1

    		Autophagy Necroptosis RIP kinase Cancer
    RIP3 activator 1 (compound C8) is a potent RIP3 activator. RIP3 activator 1 inhibits cell growth. RIP3 activator 1 induces necroptosis through the RIP3/p62/Keap1 signaling pathway. RIP3 activator 1 increases the protein expression of p-MLKL. RIP3 activator 1 induces autophagy. RIP3 activator 1 increases accumulation of LC3-II and p62 protein expression .
    RIP3 activator 1
  • HY-161741
    VinclozolinM2-2204

    		AUTOTACs Androgen Receptor Cancer
    VinclozolinM2-2204 is a androgen receptor (AR) AUTOTAC degrader, with an DC50 of 200 nM in LNCaP prostate cancer cells. VinclozolinM2-2204 induces the formation of AR +LC3 + autophagic membranes. VinclozolinM2-2204 can be used for the research of cancer .(Pink: AR inhibitor (HY-168296); Black: linker (HY-128833); Blue: CRBN Ligand (HY-168293))
    VinclozolinM2-2204
  • HY-112624K
    Dextran T5 (MW 5,000)

    Dextran 5; Dextran D5; Dextran T5(MW 4500-5500)

    		 Apoptosis Autophagy Others
    Dextran T5 (MW 5,000) is a sulfated polysaccharide anti-apoptotic and autophagic agent. Dextran T5 (MW 5,000) has sulfated groups and interacts with cell membranes by mimicking endogenous glycosaminoglycans, inhibiting the mitochondrial apoptotic pathway and delaying DNA fragmentation to exert anti-apoptotic activity. Dextran T5 (MW 5,000) also promotes the conversion of LC3-I to LC3-II and the formation of autophagosomes to activate the autophagic pathway. Dextran T5 (MW 5,000) can prolong the survival cycle of CHO cells and increase the production of recombinant erythropoietin (EPO). The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance [3].
    Dextran T5 (MW 5,000)
  • HY-170998
    ATG16L1 stabilizer-1

    		Autophagy Inflammation/Immunology
    ATG16L1 stabilizer-1 (compound A3B) is an FKBP12-independent ATG16L1 stabilizer that promotes cellular Autophagy. ATG16L1 stabilizer-1 inhibits ATG16L1 with an EC50 of 12.1 μM in the presence or absence of FKBP12. ATG16L1 stabilizer-1 alone induces GFP-LC3 puncta formation to a small extent with an EC50 of 12.0 μM .
    ATG16L1 stabilizer-1
  • HY-141882
    DC-LC3in-D5

    		Atg8/LC3 Autophagy Infection Inflammation/Immunology Cancer
    DC-LC3in-D5 acts as an autophagy inhibitor by attenuating LC3B lipidation. DC-LC3in-D5 binds with LC3B. DC-LC3in-D5 disrupts the LC3B-LBP2 interaction with an IC50 of 200 nM. DC-LC3in-D5 may contribute to anti-HCV or combination researchs in cancer through inhibiting autophagy .
    DC-LC3in-D5
  • HY-N6796
    Manumycin A
    2 Publications Verification

    		 Antibiotic Farnesyl Transferase Ras Apoptosis Phospholipase TNF Receptor Atg8/LC3 Infection Inflammation/Immunology Cancer
    Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion [3] .
    Manumycin A
  • HY-W010201
    Citronellol
    2 Publications Verification

    (±)-Citronellol; (±)-β-Citronellol

    		 Reactive Oxygen Species ERK PI3K TNF Receptor Atg8/LC3 p62 Apoptosis Necroptosis Autophagy Fungal Cardiovascular Disease Neurological Disease Cancer
    Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .
    Citronellol
  • HY-W050044
    L-Azetidine-2-carboxylic acid

    		Endogenous Metabolite PERK Atg8/LC3 Autophagy Bcl-2 Family Apoptosis Eukaryotic Initiation Factor (eIF) ATF6 Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology Cancer
    L-Azetidine-2-carboxylic acid is a proline analog. L-Azetidine-2-carboxylic acid upregulates the lipid autophagy marker LC3-II via activation of the PERK pathway. L-Azetidine-2-carboxylic acid increases pro-apoptotic BAX protein. L-Azetidine-2-carboxylic acid induces ATF6 cleavage and upregulates phosphorylated eIF2α levels. L-Azetidine-2-carboxylic acid induces ER stress, inducing protein misfolding and aggregation. L-Azetidine-2-carboxylic acid shows teratogenic, pro-inflammatory and pro-apoptotic effects [3] .
    L-Azetidine-2-carboxylic acid
  • HY-N0538
    Xylitol

    Xylite

    		 Autophagy Endogenous Metabolite Bacterial Atg7 Atg8/LC3 Metabolic Disease Cancer
    Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model [3] .
    Xylitol
  • HY-176451
    CDK9 degrader-1

    		CDK Cancer
    CDK9 degrader-1 is a selective CDK9 degrader (DC50: 0.4073 µM). CDK9 degrader-1 recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuses with lysosomes to degrade CDK9 and its partner protein Cyclin T1 (DC50: 1.215 µM). CDK9 degrader-1 induces caspase 3-mediated apoptosis. CDK9 degrader-1 has antitumor activity in a mouse HCT116 xenograft model .
    CDK9 degrader-1
  • HY-170992
    Autophagy agonist-1

    		Autophagy CDK Atg8/LC3 PINK1/Parkin Cancer
    Autophagy agonist-1 (compound 22) is an Autophagy agonist. Autophagy agonist-1 exhibits significant anticancer activity against HepG2 cells and normal cells with IC50s of 8.8 μM and > 50 μM. Autophagy agonist-1 induces G1/S phase cell cycle arrest and inhibits CDK4 and CyclinD1 expression while upregulating P21. Autophagy agonist-1 promotes the accumulation of autophagosomes and the proteins LC3 and PINK1, enhancing autophagy and mitophagy in HepG2 cells .
    Autophagy agonist-1
  • HY-W010201R
    Citronellol (Standard)

    (±)-Citronellol (Standard); (±)-β-Citronellol (Standard)

    		 Reactive Oxygen Species ERK PI3K TNF Receptor Atg8/LC3 p62 Apoptosis Necroptosis Autophagy Fungal Cardiovascular Disease Neurological Disease Cancer
    Citronellol (Standard) is the analytical standard of Citronellol. Citronellol (Standard) is an orally active inducer of apoptosis. Citronellol (Standard) can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol (Standard) can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol (Standard) can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol (Standard) exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .
    Citronellol (Standard)
  • HY-W010201S
    Citronellol-d6

    (±)-Citronellol-d6; (±)-β-Citronellol-d6

    		 Reactive Oxygen Species Isotope-Labeled Compounds Cancer
    Citronellol-d6 is deuterated labeled Citronellol (HY-W010201). Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .
    Citronellol-d6
  • HY-111137
    Puquitinib

    XC-302 free base

    		 Akt Cancer
    Puquitinib (XC-302 free base) is a multi-target inhibitor with the activity of inducing autophagy in nasopharyngeal carcinoma cells by inhibiting the PI3K/AKT/mTOR signaling pathway. Puquitinib was able to inhibit the proliferation of CNE-2 cells, showing a dose-dependent antiproliferative effect. Puquitinib induced the formation of autophagosomes and autolysosomes in CNE-2 cells, which were observed by fluorescence microscopy and electron microscopy. Puquitinib promoted the formation of LC3-II and increased the expression of beclin 1, while reducing the level of p62. Puquitinib inhibited the PI3K/AKT/mTOR pathway by reducing the expression of p-AKT and p-mTOR. Puquitinib also induced apoptosis in CNE-2 cells, and when autophagy was inhibited, the apoptosis rate was reduced, which means that autophagy may interact with apoptosis to induce cell death .
    Puquitinib
  • HY-RS08028
    MAP1LC3A Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MAP1LC3A Human Pre-designed siRNA Set A contains three designed siRNAs for MAP1LC3A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MAP1LC3A Human Pre-designed siRNA Set A
    MAP1LC3A Human Pre-designed siRNA Set A
  • HY-RS21273
    Map1lc3a Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Map1lc3a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Map1lc3a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Map1lc3a Mouse Pre-designed siRNA Set A
    Map1lc3a Mouse Pre-designed siRNA Set A
  • HY-RS27792
    Map1lc3a Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Map1lc3a Rat Pre-designed siRNA Set A contains three designed siRNAs for Map1lc3a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Map1lc3a Rat Pre-designed siRNA Set A
    Map1lc3a Rat Pre-designed siRNA Set A
  • HY-RS08029
    MAP1LC3B Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MAP1LC3B Human Pre-designed siRNA Set A contains three designed siRNAs for MAP1LC3B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MAP1LC3B Human Pre-designed siRNA Set A
    MAP1LC3B Human Pre-designed siRNA Set A
  • HY-RS18108
    Map1lc3b Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Map1lc3b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Map1lc3b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Map1lc3b Mouse Pre-designed siRNA Set A
    Map1lc3b Mouse Pre-designed siRNA Set A
  • HY-RS24582
    Map1lc3b Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Map1lc3b Rat Pre-designed siRNA Set A contains three designed siRNAs for Map1lc3b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Map1lc3b Rat Pre-designed siRNA Set A
    Map1lc3b Rat Pre-designed siRNA Set A
  • HY-RS08030
    MAP1LC3B2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MAP1LC3B2 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP1LC3B2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MAP1LC3B2 Human Pre-designed siRNA Set A
    MAP1LC3B2 Human Pre-designed siRNA Set A
  • HY-101535
    ARP101
    1 Publications Verification

    		 Atg8/LC3 MMP Cancer
    ARP101 is a potent and selective inhibitor matrix metalloproteinase-2 (MMP-2). ARP101 induces autophagy-associated cell death in cancer cells. ARP101 is effective in inducing the formation of autophagosome and conversion of LC3I into LC3II .
    ARP101
  • HY-112698
    CA-5f

    		p62 Atg8/LC3 Autophagy Apoptosis Cancer
    CA-5f is a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein, and also increases ROS production. Anti-tumor activity .
    CA-5f

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: